Hans Lanz - Concepedia

Author

Hans Lanz

Daiichi Sankyo (United States)

Also Known As

H Lanz, H. -J. Lanz, H. Lanz, H.J. Lanz, Hans J Lanz, Hans J. Lanz, Hans Joachim Lanz, Hans Lanz

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Daiichi Sankyo (United States)Thrombolysis in Myocardial Infarction Study Group Brigham and Women's Hospital Daiichi Sankyo (Germany)Harvard University

About

Hans Lanz is an author at Daiichi Sankyo (United States) specializing in medicine, pharmacotherapy, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	471
2	Public Health	5	5	132
3	Diabetes	1	1	29
4	Emergency Medicine	1	1	28
5	Geriatrics	1	1	12

Hans Lanz

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial Eri Kato, Robert P. Giugliano, Christian T. Ruff, Journal of the American Heart Association	2016	275
Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate Hamim Zahir, Karen Brown, Alexander G. Vandell, Circulation	2014	250
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation Mark S. Link, Robert P. Giugliano, Christian T. Ruff, Circulation Arrhythmia and Electrophysiology	2017	180
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial Gary E. Raskob, Nick van Es, Annelise Segers, The Lancet Haematology ThrombosisPulmonary EmbolismVenous ThrombosisMedicineDouble-dummy Trial	2016	154
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban Jack Ansell, Sasha Bakhru, Bryan Laulicht, Thrombosis and Haemostasis Fibrin DiameterThrombosisHealthy SubjectsMedicineSingle-dose Ciraparantag	2016	146
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48 David D. Berg, Christian T. Ruff, Petr Jarolı́m, Circulation	2019	138
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial Giuseppe Boriani, Christian T. Ruff, Julia Kuder, European Heart Journal	2018	132
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial Alon Eisen, Christian T. Ruff, Eugene Braunwald, Journal of the American Heart Association	2016	79
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease Arman Qamar, Elliott M. Antman, Christian T. Ruff, Journal of the American College of Cardiology ThrombosisHepatologyCardiovascular DiseaseMedicineLiver Physiology	2019	48
Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial Giuseppe Boriani, Christian T. Ruff, Julia Kuder, Thrombosis and Haemostasis	2020	41

Page 1